Piperacillin-tazobactam combination product
PreclinicalSmall molecule
Piperacillin-tazobactam combination product is one of 43 small molecule programs targeting Neutropenia. It is currently in Preclinical.
2
Indications
8
Total Trials
0
Active Trials
42
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
32 competitors in Neutropenia
#DrugCompanyPhaseTrials
1Cipro
BayerApproved
Maxipime
PfizerApproved
Merrem
BB. Braun Medical Inc.
Approved
Levaquin
WWim Janssens
Approved
Mycamine
BBaxter Healthcare Corporation
Approved
Abelcet
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Avycaz
PPhiladelphia Eye Associates
Approved
Amikin
IInsmed Incorporated
Approved
Lithobid
SSolvay Pharmaceuticals
Approved
Noxafil
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Cystic Fibrosis2 trials
Neutropenia1 trial
Piperacillin/Tazobactam for Empirical Therapy of Febrile Neutropenia
Completed·—·N/A·NCT01714570·123 enrolled
Antibiotic1 trial
AbioKin - Antibiotic Kinetics
Completed·GGruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva··NCT02609646·1,500 enrolled
Cholecystitis1 trial
2 more indications
Hematopoietic Stem Cell Transplantation1 trial
Prophylactic Piperacillin/Tazobactam in Hematopoietic Stem Cell Transplantation
Unknown status·—·N/A·NCT01714557·150 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- TThe University of Queensland